Velaglucerase alfa, sold under the brand name Vpriv, is a medication used for the treatment of Gaucher disease Type 1.

[1] It is a hydrolytic lysosomal glucocerebroside-specific enzyme, which is a recombinant form of glucocerebrosidase.

It has an identical amino acid sequence to the naturally occurring enzyme.

[3] Velaglucerase alfa was approved for medical use in the United States in February 2010,[4][5] and in the European Union in August 2010.

[3] Velaglucerase alfa is indicated for long-term enzyme-replacement therapy (ERT) in people with type-1 Gaucher disease.